Abstract
Fibroblast growth factor receptor 4 (FGFR4) has been indicated as a potential “oncogene” in various types of cancer. However, the effects and underlying mechanisms of FGFR4 on uterine leiomyosarcoma (ULMS) progression remain unclear. In this study, we firstly discovered that FGFR4 was upregulated in ULMS specimens and cell lines and closely associated with poor prognosis of ULMS patients. Cell viability and apoptosis assays showed that FGFR4 deletion inhibited cell proliferation and promoted cell apoptosis. Moreover, FGFR4 silence increased cytoplasmic GABP (GA binding protein) expression, while it decreased the nuclear GABP level to inhibit nuclear localization of GABP. Mechanistically, the inhibition ability of FGFR4 silence on nuclear localization of GABP was mediated via mammalian Ste20-like kinases 1 (MST1) activation, which could promote phosphorylation of large tumor suppressor 1 (LATS1) to reduce nuclear localization of GABP. Gain- and loss-of-functional assays indicated that FGFR4 promoted nuclear localization of GABP to inhibit cell apoptosis in ULMS. In conclusion, our findings indicated that FGFR4 inhibited cell apoptosis in ULMS via the promotion of MST1/LATS1-mediated GABP nuclear localization, shedding light on the underlying mechanism of FGFR4-induced ULMS progression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arita S et al (2005) Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 15:329–336. https://doi.org/10.1111/j.1525-1438.2005.15225.x
Babina IS, Turner NC (2017) Advances and challenges in targeting FGFR signalling in cancer Nature reviews. Cancer 17:318–332. https://doi.org/10.1038/nrc.2017.8
Bodner-Adler B, Mayerhofer K, Czerwenka K, Kimberger O, Koelbl H, Bodner K (2016) The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study. European Journal of Obstetrics & Gynecology and Reproductive Biology 207:62–67
Chen TH, Yang SF, Liu YF, Lin WL, Han CP, Wang PH (2018) Association of fibroblast growth factor receptor 4 genetic polymorphisms with the development of uterine cervical cancer and patient prognosis. Reproductive sciences 25:86–93. https://doi.org/10.1177/1933719117702250
Cho YL et al (2005) Array comparative genomic hybridization analysis of uterine leiomyosarcoma. Gynecol Oncol 99:545–551. https://doi.org/10.1016/j.ygyno.2005.07.017
Choi CH, Chung JY, Kim JH, Kim BG, Hewitt SM (2016) Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. Journal of translational medicine 14:124. https://doi.org/10.1186/s12967-016-0874-0
Crose LE et al (2014) Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J Clin Investig 124:285–296. https://doi.org/10.1172/JCI67087
Cuppens T, Tuyaerts S, Amant F (2015) Potential therapeutic targets in uterine sarcomas Sarcoma 2015:243298. https://doi.org/10.1155/2015/243298
D’Angelo E, Prat J (2010) Uterine sarcomas: a review Gynecologic oncology 116:131–139. https://doi.org/10.1016/j.ygyno.2009.09.023
Dhingra S et al (2010) Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications. International journal of clinical and experimental pathology 4:134–146
Eisinger-Mathason TS et al (2015) Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc Natl Acad Sci USA 112:E3402–E3411. https://doi.org/10.1073/pnas.1420005112
Eskander RN, Randall LM, Sakai T, Guo Y, Hoang B, Zi X (2012) Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. The journal of obstetrics and gynaecology research 38:1086–1094. https://doi.org/10.1111/j.1447-0756.2011.01841.x
Flake GP, Andersen J, Dixon D (2003) Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111:1037–1054
Fullenkamp CA et al (2016) TAZ and YAP are frequently activated oncoproteins in sarcomas Oncotarget 7:30094–30108. https://doi.org/10.18632/oncotarget.8979
Galan JA, Avruch J (2016) MST1/MST2 protein kinases: regulation and physiologic roles. Biochemistry 55:5507–5519. https://doi.org/10.1021/acs.biochem.6b00763
Kuehn B (2019) Uterine cancer concern Jama 321:336. https://doi.org/10.1001/jama.2018.21059
Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO (2012) The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 109:E2441-2450. https://doi.org/10.1073/pnas.1212021109
Li SQ et al (2013) Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS ONE 8:e76551. https://doi.org/10.1371/journal.pone.0076551
Liu-Chittenden Y et al (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP Genes & development 26:1300–1305. https://doi.org/10.1101/gad.192856.112
Maki RG et al (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas . Journal of clinical oncology : official journal of the American Society of Clin Oncol 27:3133–3140. https://doi.org/10.1200/JCO.2008.20.4495
Matsumura N et al (2006) Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis. Clin Cancer Res 12:1402–1411
Montor WR, Salas A, Melo FHM (2018) Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Molecular cancer 17:55. https://doi.org/10.1186/s12943-018-0792-2
Reichardt P (2012) The treatment of uterine sarcomas . Annals of oncology : official journal of the European Society for Med Oncol 23(Suppl 10):x151-157. https://doi.org/10.1093/annonc/mds359
Ren W et al (2008) Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma . Clinical cancer research an official journal of the American Association for Cancer Research 14:5466–5475. https://doi.org/10.1158/1078-0432.CCR-08-0562
Rosmarin AG, Resendes KK, Yang Z, McMillan JN, Fleming SL (2004) GA-binding protein transcription factor: a review of GABP as an integrator of intracellular signaling and protein-protein interactions. Blood Cells Mol Dis 32:143–154
Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, Lee E (2013) The way Wnt works: components and mechanism. Growth Factors 31:1–31. https://doi.org/10.3109/08977194.2012.752737
Sanci M, Dikis C, Inan S, Turkoz E, Dicle N, Ispahi C (2011) Immunolocalization of VEGF VEGF receptors EGF-R and Ki-67 in leiomyoma cellular leiomyoma and leiomyosarcoma. Acta Histochem 113:317–325. https://doi.org/10.1016/j.acthis.2010.01.001
Sawa C, Goto M, Suzuki F, Watanabe H, Sawada J, Handa H (1996) Functional domains of transcription factor hGABP beta1/E4TF1–53 required for nuclear localization and transcription activation. Nucleic Acids Res 24:4954–4961. https://doi.org/10.1093/nar/24.24.4954
Sette G et al (2012) EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS ONE 7:e46891. https://doi.org/10.1371/journal.pone.0046891
Sugiyama N et al (2010) Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Can Res 70:7851–7861. https://doi.org/10.1158/0008-5472.CAN-10-1223
Tremblay AM et al (2014) The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. Cancer Cell 26:273–287. https://doi.org/10.1016/j.ccr.2014.05.029
Tsai S-J, Wu M-H, Chen H-M, Chuang P-C, Wing L-YC (2002) Fibroblast growth factor-9 is an endometrial stromal growth factor. Endocrinology 143:2715–2721
Tse K, Ngan H (2018) World trends of incidence of gynecologic malignancies in young women. Eur J Gynaecol Oncol 39:871–876
Turunen SP et al (2019) FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1/2-dependent apoptosis. Cell Death Differ. https://doi.org/10.1038/s41418-019-0321-x
Usmanova N, Tomilin N, Zhivotovsky B, Kropotov A (2011) Transcription factor GABP/NRF-2 controlling biogenesis of mitochondria regulates basal expression of peroxiredoxin V but the mitochondrial function of peroxiredoxin V is dispensable in the dog. Biochimie 93:306–313. https://doi.org/10.1016/j.biochi.2010.10.002
Valzacchi GMR, Rosas P, Uzal M, Gil SJ, Viglierchio VT (2019) Incidence of leiomyosarcoma at surgery for presumed uterine fibroids in different age groups. Journal of minimally invasive gynecology. https://doi.org/10.1016/j.jmig.2019.06.013
van Graaf WT et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised double-blind placebo-controlled phase 3 trial. Lancet 379:1879–1886. https://doi.org/10.1016/S0140-6736(12)60651-5
Wu H et al (2013) The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. Cell reports 3:1663–1677. https://doi.org/10.1016/j.celrep.2013.04.020
Yasutake N et al (2018) Insulin-like growth factor II messenger RNA-binding protein-3 is an independent prognostic factor in uterine leiomyosarcoma. Histopathology 72:739–748. https://doi.org/10.1111/his.13422
Yu S, Cui K, Jothi R, Zhao DM, Jing X, Zhao K, Xue HH (2011) GABP controls a critical transcription regulatory module that is essential for maintenance and differentiation of hematopoietic stem/progenitor cells. Blood 117:2166–2178. https://doi.org/10.1182/blood-2010-09-306563
Zaid TM et al (2013) Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer . Clinical cancer research an official journal of the American Association for Cancer Research 19:809–820. https://doi.org/10.1158/1078-0432.CCR-12-2736
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, P., Zhang, H. & Wang, Y. FGFR4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma. Cell Tissue Res 383, 865–879 (2021). https://doi.org/10.1007/s00441-020-03296-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00441-020-03296-5